Apatinib for adults with recurring atypical or malignant meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether apatinib can shrink or control recurring atypical/malignant meningioma that has come back after surgery and radiation. It focuses on adults with measurable regrowth on MRI and good overall health to safely take an oral medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your biopsy or surgery confirmed atypical or malignant meningioma.
- Your MRI shows the tumor has come back (at least 1 cm and visible on at least two 5-mm slices), or a new biopsy/surgery also confirms the same diagnosis.
- You’ve had surgery and radiation before, and your last radiation was at least 4 weeks ago (and last chemotherapy at least 4 weeks ago if you had it).
- You can swallow the apatinib tablet whole, and you have no major swallowing problems or severe stomach/intestine issues that prevent taking pills.
- Your body can handle treatment: generally good heart/lung/liver/kidney function, no uncontrolled bleeding/clotting problems, and expected survival of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding apatinib to temozolomide and etoposide helps children whose medulloblastoma has come back. It aims to slow the tumor and improve outcomes after standard treatments.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
This trial tests a pill called regorafenib for people whose meningioma (a brain tumor) has come back and cannot be treated with surgery or radiation. The goal is to see if regorafenib can help stop the tumor from growing further.
This trial studies whether apatinib, a targeted medicine, combined with an immunotherapy treatment can shrink or control neuroblastoma that has come back or does not respond to prior treatment. Because it is a Phase I/II single-group study, everyone receives the planned treatment and researchers watch side effects and response.
Hear when a new Recurrent Atypical/malignant Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.